NBP
NovaBridge Biosciences
1.40$
+0.0%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Cash Flow
NovaBridge Biosciences (NBP) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -16 million $. Tick rows to compare them in a chart.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q1 20 | Q2 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q3 22 | Q1 23 | Q2 23 | Q3 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -32 | -32 | -91 | -126 | -195 | -195 | -263 | -175 | -175 | -233 | -221 | -221 | -265 | -1,989 | -286 | -43 | -2,119 | – | – | – | – | 8.4 | -11 | – | – | 13 | -15 | -16 | -16 | -34 | |
| 0.7 | 0.7 | 1.0 | 4.3 | 3.6 | 3.6 | 4.0 | 4.6 | 4.6 | 5.5 | 6.8 | 6.8 | 9.1 | 9.1 | 17 | 3.6 | 12 | – | – | – | – | 0.2 | 0.2 | – | – | 1.5 | 0.2 | 2.2 | 2.2 | 6.1 | |
| 1.0 | 1.0 | 1.0 | 0.6 | 257 | 257 | 0.5 | 115 | 115 | 163 | 167 | 167 | 137 | 137 | 98 | 80 | 67 | 67 | 29 | -14 | 8.3 | 2.1 | 0.8 | 2.2 | 2.1 | 10 | 3.9 | 3.4 | 3.4 | 21 | |
| 75 | 75 | 20 | -6.3 | 32 | 32 | 29 | -4.7 | -4.7 | -3.6 | 101 | 101 | -12 | 235 | 20 | 3.0 | 235 | – | – | – | – | 18 | -1.1 | – | – | 50 | 10 | -2.9 | -2.9 | 54 | |
| 2.1 | 2.1 | 3.3 | 7.0 | 1.0 | 1.0 | 2.7 | 0.1 | 0.1 | 4.6 | 2.0 | 2.0 | 13 | 2.0 | 9.4 | 1.4 | 38 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.5 | 0.5 | 1.0 | |
| 7.2 | 7.2 | 1.5 | -6.4 | 79 | 79 | -23 | 15 | 15 | -287 | -191 | -191 | -173 | -782 | 250 | 37 | 404 | – | – | – | – | – | – | – | – | -0.4 | – | 6.1 | 6.1 | – | |
| – | – | – | – | – | – | – | 5.3 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | -5.1 | -0.2 | – | – | 35 | – | – | 35 | – | – | – | – | 0.0 | 0.0 | – | – | 0.0 | 0.0 | – | – | – | |
| 75 | 75 | 1,330 | -0.1 | -15 | -15 | 69 | 327 | 327 | 1,942 | 243 | 243 | 54 | -2,787 | 18 | 2.6 | -2,787 | – | – | – | – | 0.0 | 0.0 | – | – | 433 | -3.0 | 0.4 | 0.4 | 431 | |
| 46 | 46 | 1,328 | -152 | -132 | -132 | -136 | 183 | 183 | 1,400 | -204 | -204 | -413 | -5,441 | 94 | 14 | -4,385 | -226 | – | – | – | -73 | -11 | – | – | 446 | -17 | -213 | – | – | |
| -34 | -34 | -94 | -133 | -195 | -195 | -266 | -175 | -175 | -237 | -223 | -223 | -278 | -1,991 | -295 | -44 | -2,157 | – | – | – | – | 8.4 | -11 | – | – | 13 | -15 | -17 | -17 | -35 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.